Other studies in B-ALL demonstrated Gal-9-dependent activation of tumoral AKT and ERK pathways, thus rationalizing Gal-9 inhibition as a promising therapeutic approach for patients with B-ALL and other hematologic malignancies [117]. Here, LGALS9 is linked to acute lymphoblastic leukemia.